Ameritas Investment Partners Inc. maintained its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,622 shares of the biopharmaceutical company’s stock at the end of the second quarter. Ameritas Investment Partners Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,779,000 at the end of the most recent quarter.
Several other hedge funds also recently made changes to their positions in the company. Alpha Windward LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 0.3% during the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 1 shares during the period. Cleararc Capital Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 0.3% during the 1st quarter. Cleararc Capital Inc. now owns 1,850 shares of the biopharmaceutical company’s stock worth $717,000 after acquiring an additional 5 shares during the period. Regentatlantic Capital LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 0.9% during the 2nd quarter. Regentatlantic Capital LLC now owns 537 shares of the biopharmaceutical company’s stock worth $264,000 after acquiring an additional 5 shares during the period. Capital Planning Advisors LLC increased its position in Regeneron Pharmaceuticals by 2.1% during the 2nd quarter. Capital Planning Advisors LLC now owns 582 shares of the biopharmaceutical company’s stock worth $286,000 after purchasing an additional 12 shares in the last quarter. Finally, Sequoia Financial Advisors LLC increased its position in Regeneron Pharmaceuticals by 1.7% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 712 shares of the biopharmaceutical company’s stock worth $350,000 after purchasing an additional 12 shares in the last quarter. Institutional investors and hedge funds own 67.41% of the company’s stock.
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded down 0.94% during trading on Friday, reaching $442.96. The company had a trading volume of 718,075 shares. The stock has a 50 day moving average price of $457.32 and a 200 day moving average price of $454.85. The firm has a market capitalization of $46.97 billion, a PE ratio of 44.44 and a beta of 1.62. Regeneron Pharmaceuticals, Inc. has a 12 month low of $325.35 and a 12 month high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.67 by $1.50. The business had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.82 earnings per share. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post $14.95 EPS for the current year.
In related news, SVP Robert E. Landry sold 526 shares of the business’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $472.19, for a total value of $248,371.94. Following the sale, the senior vice president now owns 9,099 shares of the company’s stock, valued at approximately $4,296,456.81. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Sanofi purchased 166,415 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The stock was bought at an average cost of $480.93 per share, for a total transaction of $80,033,965.95. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 89,468 shares of company stock worth $42,312,448. 10.80% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This story was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://sportsperspectives.com/2017/10/14/regeneron-pharmaceuticals-inc-regn-holdings-maintained-by-ameritas-investment-partners-inc.html.
A number of analysts recently issued reports on REGN shares. Piper Jaffray Companies increased their target price on shares of Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 20th. BMO Capital Markets reissued a “market perform” rating and set a $421.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 21st. Canaccord Genuity set a $484.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, June 20th. Raymond James Financial, Inc. reissued an “outperform” rating and set a $547.00 target price (up previously from $475.00) on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 22nd. Finally, Leerink Swann reissued an “outperform” rating and set a $573.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 22nd. Three analysts have rated the stock with a sell rating, fourteen have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $489.92.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.